713 related articles for article (PubMed ID: 27668807)
1. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
Long C; Amoasii L; Bassel-Duby R; Olson EN
JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
[TBL] [Abstract][Full Text] [Related]
2. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments.
Laurent M; Geoffroy M; Pavani G; Guiraud S
Cells; 2024 May; 13(10):. PubMed ID: 38786024
[TBL] [Abstract][Full Text] [Related]
3. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
[TBL] [Abstract][Full Text] [Related]
5. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy.
Bengtsson NE; Hall JK; Odom GL; Phelps MP; Andrus CR; Hawkins RD; Hauschka SD; Chamberlain JR; Chamberlain JS
Nat Commun; 2017 Feb; 8():14454. PubMed ID: 28195574
[TBL] [Abstract][Full Text] [Related]
6. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
Choi E; Koo T
Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
[TBL] [Abstract][Full Text] [Related]
7. Advances in CRISPR/Cas9 Genome Editing for the Treatment of Muscular Dystrophies.
Fatehi S; Marks RM; Rok MJ; Perillat L; Ivakine EA; Cohn RD
Hum Gene Ther; 2023 May; 34(9-10):388-403. PubMed ID: 37119122
[TBL] [Abstract][Full Text] [Related]
8. CRISPR Correction of Duchenne Muscular Dystrophy.
Min YL; Bassel-Duby R; Olson EN
Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
[TBL] [Abstract][Full Text] [Related]
9. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas correction of muscular dystrophies.
Zhang Y; Nishiyama T; Olson EN; Bassel-Duby R
Exp Cell Res; 2021 Nov; 408(1):112844. PubMed ID: 34571006
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy.
Happi Mbakam C; Lamothe G; Tremblay G; Tremblay JP
Neurotherapeutics; 2022 Apr; 19(3):931-941. PubMed ID: 35165856
[TBL] [Abstract][Full Text] [Related]
12. Correction of muscular dystrophies by CRISPR gene editing.
Chemello F; Bassel-Duby R; Olson EN
J Clin Invest; 2020 Jun; 130(6):2766-2776. PubMed ID: 32478678
[TBL] [Abstract][Full Text] [Related]
13. Genome engineering: a new approach to gene therapy for neuromuscular disorders.
Nelson CE; Robinson-Hamm JN; Gersbach CA
Nat Rev Neurol; 2017 Nov; 13(11):647-661. PubMed ID: 28960187
[TBL] [Abstract][Full Text] [Related]
14. Restoration of dystrophin expression and correction of Duchenne muscular dystrophy by genome editing.
Aslesh T; Erkut E; Yokota T
Expert Opin Biol Ther; 2021 Aug; 21(8):1049-1061. PubMed ID: 33401973
[No Abstract] [Full Text] [Related]
15. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
Nelson CE; Wu Y; Gemberling MP; Oliver ML; Waller MA; Bohning JD; Robinson-Hamm JN; Bulaklak K; Castellanos Rivera RM; Collier JH; Asokan A; Gersbach CA
Nat Med; 2019 Mar; 25(3):427-432. PubMed ID: 30778238
[TBL] [Abstract][Full Text] [Related]
17. CRISPR Therapeutics for Duchenne Muscular Dystrophy.
Erkut E; Yokota T
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163754
[TBL] [Abstract][Full Text] [Related]
18. Making gene editing a therapeutic reality.
Conboy I; Murthy N; Etienne J; Robinson Z
F1000Res; 2018; 7():. PubMed ID: 30613384
[TBL] [Abstract][Full Text] [Related]
19. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.
Amoasii L; Long C; Li H; Mireault AA; Shelton JM; Sanchez-Ortiz E; McAnally JR; Bhattacharyya S; Schmidt F; Grimm D; Hauschka SD; Bassel-Duby R; Olson EN
Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187645
[TBL] [Abstract][Full Text] [Related]
20. AMPK is mitochondrial medicine for neuromuscular disorders.
Mikhail AI; Ng SY; Mattina SR; Ljubicic V
Trends Mol Med; 2023 Jul; 29(7):512-529. PubMed ID: 37080889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
